Adel key facts
- Operator of a medical research firm intended to develop neuropathic treatments and diagnostic systems.
- It has raised $12.7M; the latest was Later Stage VC ($30K) in Apr 2026.
- Notable investors include Tech Incubator Program for Startup, Korea Investment Partners, Samsung Venture Investment, Smilegate Investment, STIC Ventures — 17 tracked in total.
- Status: Privately Held (backing).
Who backs Adel
17+- ·The complete investor list: 17 names
- ·Watch Adel: the Monday email on marks, rounds and moves
Adel funding rounds
No funding rounds for Adel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Adel investors
17 investors are on record for Adel, including Tech Incubator Program for Startup, Korea Investment Partners, Samsung Venture Investment and Smilegate Investment. By type, the record holds 4 venture capital firms and 1 hedge fund.
About Adel
Operator of a medical research firm intended to develop neuropathic treatments and diagnostic systems. The company researches Alzheimer's disease therapeutics by inhibiting tau aggregation and propagation over other antibodies in clinical trials, enabling patients to receive dementia treatment.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 20
- Website
- adelpharm.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Adel doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.